Coming soon..

For studies requiring genetically complex mouse models, Mirimus is researching employable methods to amalgamate both CRISPR-Cas9 genome editing and RNAi GEMM technology. Complex disease models are developed by CRISPR-Cas9 editing via non-homologous end joining (NHEJ) and/or homology directed repair (HDR) pathway followed by shRNA knockin which allows investigators to induce gene knockdown to mimic the effects of therapeutic administration and reverse gene knockdown during the onset of the disease. In this end, Mirimus’ innovative pipeline will provide in the future a unique platform for temporally and spatially exploring a complex genetic disease model, which eliminates the lengthy and expensive lead time and cost required for intercrossing and excessive animal husbandry.

For more information please contact info@mirimus.com.